EW - Conference and earnings call announcements

Edwards Lifesciences (NYSE:EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) released by the Centers for Medicare & Medicaid Services (CMS):"Edwards is pleased that this updated policy represents an important step toward improving and expanding patient access to TAVR while reinforcing the value of a multidisciplinary Heart Team. Aortic stenosis is a serious, progressive disease, and delays in evaluation, diagnosis and treatment increase the risk of irreversible heart damage and hospitalization, leading to poorer outcomes and higher healthcare costs, as well as an increased risk of death. The mod

Edwards Lifesciences Corporation (NYSE:EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.Bernard Zovighian, chief executive officer, is scheduled to present at 10:00 a.m. ET. Doretta Mistras, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day.About Edwards LifesciencesEdwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and p

Edwards Lifesciences (NYSE:EW) today announced it will participate in the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026. Bernard Zovighian, chief executive officer, will participate in a fireside chat at 3:40 p.m. Pacific Time. A live webcast of the discussion will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthca

Edwards Lifesciences Corporation (NYSE:EW) today announced its chief financial officer, Scott Ullem, is scheduled to present at two upcoming conferences: Tuesday, March 10, 2026 at 10:00 a.m. ET at the Barclays 28th Annual Global Healthcare Conference Wednesday, March 11, 2026 at 10:00 a.m. ET at the Leerink Global Healthcare Conference A live webcast of each presentation will be available on the Edwards investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakth

Edwards Lifesciences Corporation (NYSE:EW) today announced it will participate in Citi's Unplugged Medtech and Life Sciences Access Day on February 26, 2026. Scott Ullem, chief financial officer, is scheduled to present at 10:15 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeho

Edwards Lifesciences Corporation (NYSE:EW) today announced it will participate in the TD Cowen 46th Annual Health Care Conference on Monday, Mar. 2, 2026. Scott Ullem, chief financial officer, is scheduled to present at 9:50 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholder

Edwards Lifesciences Corporation (NYSE:EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-

Edwards Lifesciences (NYSE:EW) today announced it will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, will participate in a fireside chat at 10:40 a.m. Pacific Time. A live webcast of the discussion will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and p

Edwards Lifesciences Corporation (NYSE:EW) today announced it will participate in the TD Cowen 45th Annual Health Care Conference on Tuesday, Mar. 4, 2025. Scott Ullem, chief financial officer, is scheduled to present at 9:50 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholde

Edwards Lifesciences Corporation (NYSE:EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, wo

Edwards Lifesciences Corporation (NYSE:EW) today announced it will participate in the Wells Fargo Healthcare Conference on Thursday, Sept. 5, 2024. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, are scheduled to present at 10:15 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving an

Edwards Lifesciences Corporation (NYSE:EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, are scheduled to present at 10:30 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and en

Edwards Lifesciences Corporation (NYSE:EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2024. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for p

IRVINE, Calif., Jan. 5, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023.   Michael A. Mussallem, chairman and chief executive officer, is scheduled to present at 11:15 a.m. PT.  Bernard Zovighian, president and incoming chief executive officer, and Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, w

IRVINE, Calif., May 23, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) today announced it is scheduled to present at the Bernstein 38th Annual Strategic Decisions Conference on Thursday, June 2, 2022.   Michael A. Mussallem, chairman and chief executive officer, is scheduled to speak to conference attendees at 1:30 p.m. ET.  A live webcast of the presentation will be available to all interested parties on the Edwards Lifesciences investor relations website at http://ir.edwards.com/.  An archived version of the webcast will be available later that day on the Ed

IRVINE, Calif., Jan. 5, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) today announced it will participate at the J.P. Morgan Healthcare Conference on Monday, January 10, 2022.  Michael A. Mussallem, chairman and chief executive officer, is scheduled to present virtually at 11:15 a.m. ET.  A live webcast of the presentation will be available to all interested parties on the Edwards Lifesciences investor relations website at http://ir.edwards.com/.  An archived version of the webcast will be available later that day on the Edwards' investor relations website. A

IRVINE, Calif., April 20, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended March 31, 2021.  First Quarter Highlights and 2021 Outlook Sales grew 8 percent to $1.2 billion; underlying1 sales grew 5 percent TAVR sales grew 7 percent; underlying sales grew 4 percent EPS of $0.54 exceeded expectations Received approval for a U.S. pivotal trial for TAVR in moderate AS patients Received TAVR approval in Japan for patients at low surgical risk First patients were treated with EVOQUE Eos transcatheter mitral replacement syste

IRVINE, Calif., April 13, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended March 31, 2021 after the market closes on Tuesday, April 20, 2021, and will host a conference call at 5:30 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893.  For 72 hours following the call, an audio replay can be accessed by dialing (877) 660-6853 or (201) 612-7415 and using conference number 13717235.  The call will also be available via live or archived webcast on th

IRVINE, Calif., Jan. 27, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2020.  Fourth Quarter Highlights and Outlook Q4 sales increased 1 percent to $1.2 billion; underlying1 sales flat Q4 TAVR sales grew 2 percent; underlying sales flat Q4 EPS was $0.49; adjusted1 EPS grew 2 percent to $0.50 December investor conference highlighted 2021 and long-term outlook 2021 guidance reiterated with sales growth expected in the mid-teens "Despite unprecedented challenges in 2020, I'm proud of our team's steadfast dedication to  patients and advancing Edwards' long-term strategy.  We continued to invest in developing so

IRVINE, Calif., Jan. 13, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2020 after the market closes on Wednesday, January 27, 2021, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893.  For 72 hours following the call, an audio replay can be accessed by dialing (877) 660-6853 or (201) 612-7415 and using conference number 13714408.  The call will also be available via live or archived webcast on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edward